Source: NIH
Date: January 11, 2010
URL:
http://clinicaltrials.gov/ct2/show/NCT01046370 A pilot study of Amygdala retraining program in patients with
Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
-------------------------------------------------------------
This study is currently recruiting participants.
Verified by Mayo Clinic, January 2010
First Received: January 11, 2010 No Changes Posted
Sponsor: Mayo Clinic
Information provided by: Mayo Clinic
ClinicalTrials.gov Identifier: NCT01046370
Purpose
The purpose of this pilot study is to gather preliminary data on the
efficacy and feasibility of the Amygdala Retraining Program (ARP),
a mind-body practice versus a control (C) on fatigue, quality of life
and sleep in patients with Chronic Fatigue Syndrome (CFS), Chronic
Fatigue (CF) and Fibromyalgia (FM).
CFS, CF and FM are incapacitating disorders characterized by profound
fatigue, muscle pain, impaired memory, insomnia, and post-exertional
malaise (Fukuda 1994). Current literature points to a centrally
sensitized state in CFS, CF and FM (Meeus 2007). The ARP attempts to
retrain this neuronal network through mind-body practices such as
cognitive restructuring via neurolinguistic programming, yoga based
breathing and simple mindfulness based meditation. A case series of
33 patients with CFS and ARP reported improvement in 92% of patients
with two-thirds of patients reaching 80-100% of pre-illness levels of
health (Gupta 2009). However ARP has never been formally studied in
CFS.
We propose to gather preliminary data on the efficacy and feasibility
of ARP versus C on fatigue, quality of life and sleep in 30 patients
with CFS, CF and FM. All participants will undergo standard clinical
treatment which consist of a 2 day self-management program in the
Chronic Fatigue Clinic. Following this, participants will be
randomized into the ARP or C group. The ARP group will receive an
additional 2.5 hour training surrounding core concepts of the ARP
program. They will then be given the ARP DVD program and booklet, to
reinforce and continue the practice. They will then receive scheduled
bi-monthly phone calls for 3 months from a study investigator for
support. The C group will receive only standard care. However they
will receive a complementary copy of the ARP program at the end of
the study (6 month time point) as a gift for participation in the
study.
Preliminary data on efficacy will be assessed at baseline, 1, 3 and
6 months using the following validated questionnaires:
Multidimensional Fatigue Inventory (MDFI), Short form-36 (SF36)
Fibromyalgia Impact Questionnaire (FIQ), Epworth Sleep Scale (ESS)
and Measure Your Medical Outcome Profile (MYMOP-2). Feasibility
will be assessed by evaluation of a daily practice log where patients
record the total time spent daily in the practice of ARP and any
specific difficulties they encountered in the practice of the program.
------------------------------------------------------------------
Condition Intervention
------------------------------------------------------------------
Chronic Fatigue Syndrome Behavioral: Amygdala Retraining Program
Chronic Fatigue
Fibromyalgia
------------------------------------------------------------------
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment,
Efficacy Study
Official Title: A Pilot Study of Amygdala Retraining Program (ARP)
Versus Control (C) in Patients With Chronic Fatigue
Syndrome (CFS), Chronic Fatigue (CF) and Fibromyalgia
(FM)
Resource links provided by NLM:
MedlinePlus related topics: Chronic Fatigue Syndrome Fibromyalgia
U.S. FDA Resources
http://www.nlm.nih.gov/medlineplus/ http://www.nlm.nih.gov/medlineplus/chronicfatiguesyndrome.html http://www.nlm.nih.gov/medlineplus/fibromyalgia.html http://clinicaltrials.gov/ct2/info/fdalinks Further study details as provided by Mayo Clinic:
Primary Outcome Measures:
* chronic fatigue syndrome, chronic fatigue and fibromyalgia
symptom severity [Time Frame: 6 months] [Designated as safety
issue: No]
Secondary Outcome Measures:
* fatigue as assessed by Multidimensional Fatigue Inventory (MDFI)
and Epworth Sleep Scale (ESS) [Time Frame: 6 months] [Designated
as safety issue: No]
* pain as assessed by the Fibromyalgia Impact Questionnaire (FIQ)
and Measure Your Medical Outcome Profile (MYMOP-2) [Time Frame: 6
months] [Designated as safety issue: No]
* quality of life as assessed by the Short Form-36 (SF-36) [Time
Frame: 6 months] [Designated as safety issue: No]
Estimated Enrollment: 30
Study Start Date: October 2009
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: June 2010 (Final data collection
date for primary outcome measure)
----------------------------------------------------------------------
Arms Assigned Interventions
----------------------------------------------------------------------
ARP Behavioral: Amygdala Retraining Program
intervention: The Amygdala Retraining Program (ARP) attempts to
Experimental retrain the sensitized neuronal network present in
patients with Chronic Fatigue Syndrome, Chronic
Fatigue and Fibromyalgia through mind-body practices
such as cognitive restructuring via neurolinguistic
programming, yoga based breathing and simple
mindfulness based meditation.
No intervention:
No Intervention
----------------------------------------------------------------------
Eligibility
Ages Eligible for Study: 18 Years to 59 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
* meet CDC criteria for Chronic Fatigue Syndrome, have been diagnosed
with chronic fatigue, or meet the American College of Rheumatology
criteria for fibromyalgia
* access to a DVD player
Exclusion Criteria:
* untreated hypo or hyper parathyroidism
* untreated adrenal disorders
* untreated diabetes
* multiple sclerosis
* acute or chronic hepatitis
* history of cancer
* untreated depression
* chronic steroid use
* acute inflammatory rheumatological conditions
* untreated obstructive sleep apnea
* narcolepsy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01046370
Contacts
Contact: Ann Vincent, MBBS, MD 507-284-3244
vincent.ann@mayo.edu Locations
United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Principal Investigator: Ann Vincent, MBBS, MD
Principal Investigator: Lana L Abboud
Sub-Investigator: Connie A Luedtke, RN
Sub-Investigator: Janet A Guderian, RN
Sub-Investigator: Loren L Toussaint, PhD
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Ann Vincent, MBBS, MD Mayo Clinic
More Information
No publications provided
Responsible Party: Mayo Clinic (Ann Vincent, MBBS, MD)
Study ID Numbers: 09-003509
Study First Received: January 11, 2010
Last Updated: January 11, 2010
ClinicalTrials.gov Identifier: NCT01046370
http://clinicaltrials.gov/ct2/show/NCT01046370 History of Changes
http://clinicaltrials.gov/ct2/archive/NCT01046370 Health Authority: United States: Institutional Review Board
Additional relevant MeSH terms:
Disease
Fatigue
Fibromyalgia
Myofascial Pain Syndromes
Nervous System Diseases
Central Nervous System Diseases
Encephalomyelitis
Rheumatic Diseases
Fatigue Syndrome, Chronic
Virus Diseases
Signs and Symptoms
Pathologic Processes
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Syndrome
ClinicalTrials.gov processed this record on January 14, 2010
--------
(c) 2010 National Institutes of Health